The purpose of this study is to investigate the safety of an investigational medication when given alone or with an antibody that targets a protein called PD-L1. PD-L1 is involved in the body's immune response, and targeting it can help enhance the body's ability to fight cancer. This study focuses on individuals with advanced or metastatic cancer, which means the cancer has spread to other parts of the body.
Participants in this study will receive either the investigational medication by itself or in combination with the antibody targeting PD-L1. The study will monitor the safety of these treatments and gather information on any side effects. Participants will need to swallow capsules as part of the treatment process.
- Who can participate: Adults with advanced or metastatic cancer who have stopped previous cancer treatments and have adequate organ function can participate. They must have an ECOG performance status of 1 or less and be able to swallow capsules.
- Study details: Participants will take the investigational medication alone or with a PD-L1 targeting antibody. A placebo is not used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand
